XML 25 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies - Revenue Recognition, PPE, Licensing and Research (Details) - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Research and Product Development      
Product development and research costs $ 1,666,356 $ 1,214,851  
Investments Available for Sale      
Fair value of investments 24,821,682   $ 24,648,459
Gross unrealized losses 216,256    
Gross unrealized gains 26,260    
Realized gains 1,425    
Realized losses 4,417    
Research and Development      
Research and Development Expense $ 1,666,356 $ 1,214,851  
Baxter Healthcare Organization      
Licensing Fees      
Useful life 1 year